Tiziana Life Sciences Ltd (NASDAQ: TLSA)’s stock price has soared by 6.57 in relation to previous closing price of 1.37. Nevertheless, the company has seen a gain of 2.10% in its stock price over the last five trading days. globenewswire.com reported 2025-05-23 that NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced advancements in moderate Alzheimer’s disease treatment, showcased in a recent feature on a national public radio station across the United States. The advancement involves the use of Tiziana’s novel nasal spray, foralumab, which is designed to combat brain inflammation, marking a step forward in moderate Alzheimer’s research and treatment.
Is It Worth Investing in Tiziana Life Sciences Ltd (NASDAQ: TLSA) Right Now?
Additionally, the 36-month beta value for TLSA is -0.08. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for TLSA is 69.11M and currently, short sellers hold a 1.04% ratio of that float. The average trading volume of TLSA on June 12, 2025 was 400.27K shares.
TLSA’s Market Performance
TLSA’s stock has seen a 2.10% increase for the week, with a -2.67% drop in the past month and a 2.10% gain in the past quarter. The volatility ratio for the week is 4.19%, and the volatility levels for the past 30 days are at 5.91% for Tiziana Life Sciences Ltd The simple moving average for the past 20 days is 2.49% for TLSA’s stock, with a 40.85% simple moving average for the past 200 days.
Analysts’ Opinion of TLSA
Many brokerage firms have already submitted their reports for TLSA stocks, with B. Riley Securities repeating the rating for TLSA by listing it as a “Buy.” The predicted price for TLSA in the upcoming period, according to B. Riley Securities is $8 based on the research report published on December 22, 2020 of the previous year 2020.
TLSA Trading at 14.61% from the 50-Day Moving Average
After a stumble in the market that brought TLSA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.56% of loss for the given period.
#####
#####
Stock Fundamentals for TLSA
The total capital return value is set at -0.45. Equity return is now at value -250.49, with -101.10 for asset returns.
Based on Tiziana Life Sciences Ltd (TLSA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -20.42. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -112.81.
Currently, EBITDA for the company is -17.14 million with net debt to EBITDA at 2.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.02.
Conclusion
In conclusion, Tiziana Life Sciences Ltd (TLSA) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
